Evidence map›Paper›PMID 28582842›Full record

ArticleCancer biomarkers : section A of Disease markers2017

Chitotriosidase, a marker of innate immunity, is elevated in patients with primary breast cancer.

Mya Sanda Thein, Anita Kohli, Rohit Ram, Maria Clara Ingaramo, Alka Jain, Neal S Fedarko

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Mya Sanda TheinDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Anita KohliDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Rohit RamDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Maria Clara IngaramoDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Alka JainDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Neal S FedarkoDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Johns Hopkins University · US

Funding

Translational Research Training Program in Gerontology and GeriatricsT32AG000120 · NIA · JOHNS HOPKINS UNIVERSITY · PI FEDARKO, NEAL S · 1986 to 2012
$4.2M
Summer Research Training in Aging for Medical StudentsT35AG026758 · NIA · JOHNS HOPKINS UNIVERSITY · PI Stephanie Nothelle, Sevil Yasar · 2005 to 2026
$1.9M
Continuous Wave Electron Paramagnetic Resonance ImagingZ01BC010478 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHERUKURI, MURALI · 2003 to 2008
$732k
Intramural NIH HHS Z01 BC010478NIA NIH HHS T32 AG000120NIA NIH HHS T35 AG026758
6 · The paper itself

Abstract

backgroundCancer progression has been associated with altered immune cell function and activation. Neopterin, which is secreted by interferon-γ stimulated macrophages, exhibits an association with multiple cancer types and metastatic disease. Chitotriosidase, which is secreted by chronically activated macrophages and granulocyte-macrophage colony-stimulating factor stimulated neutrophils has not been studied in the setting of cancer.

objectiveThe goal of this discovery study was to screen chitotriosidase for diagnostic capacity in detecting cancer and compare its operating characteristics with those of neopterin.

methodsSerum from subjects with breast (n= 66) or prostate (n= 70) cancer, and from 204 subjects free of malignant disease were studied. Chitotriosidase was measured by enzyme activity assay, while neopterin was measured by a competitive enzyme immunoassay. Statistical analyses included group comparisons by Mann Whitney U test, diagnostic capacity by receiver operating characteristics (ROC) curve analysis and biomarker associations with physiologic and clinical measures by Spearman correlation.

resultsChitotriosidase activity was significantly higher in both cancer types compared with gender matched controls, though only in breast cancer was the diagnostic capacity significant (area under the ROC curve of 0.97 ± 0.01). In contrast, neopterin was significantly elevated in prostate cancer and exhibited discriminatory capacity (area under the ROC curve of 0.76 ± 0.05). Age, BMI, % body fat and metastasis were variables that correlated with neopterin, but not chitotriosidase levels.

conclusionsThe operating characteristics of serum chitotriosidase were different from neopterin and further analysis of chitotriosidase as a biomarker for breast cancer is warranted.

Indexed as

AgedBiomarkers, TumorBreast NeoplasmsCase-Control StudiesFemaleHexosaminidasesHumansImmunity, InnateMaleMiddle AgedNeopterinProstatic NeoplasmsBiomarkers, TumorchitotriosidaseHexosaminidasesNeopterincancerchitotriosidasemacrophagesNeopterin

Identifiers

PMID28582842
PMCPMC5518624
OpenAlexW2620705936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.